cagrilintide trial New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk Once-weekly cagrilintide for weight management

Increased Tolerance and Dependence: Regularly mixing NyQuil and alcohol leads to increased tolerance, meaning higher doses are needed to achieve the same effects, which further compounds health risks

Feels very effective

The natural hormone does three things

Scott Brunner of the Alliance for Pharmacy Compounding has described this as the start of a "protracted process." Even under the most optimistic scenario, broad clinical availability of legally compounded versions of these peptides is likely a mid-to-late 2026 proposition at the earliest and possibly longer if the political or regulatory environment shifts

Most researchers report that meaningful changes in autoimmune-related symptoms require 4 to 12 weeks of consistent use